diaDexus, Inc. – ‘8-K’ for 10/3/02

On:  Friday, 10/4/02, at 2:25pm ET   ·   For:  10/3/02   ·   Accession #:  1169232-2-1974   ·   File #:  0-26483

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         4      9K 
 2: EX-99.1     Press Release Issued October 3, 2002.                  3     14K 

8-K   —   Current Report
Document Table of Contents

8-K
1st Page of 4
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 -------------------------

FORM 8-K

CURRENT REPORT

 Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 Date of Report (Date of earliest event reported): October 3, 2002

VAXGEN, INC.
(Exact name of Registrant as Specified in its Charter)

      DELAWARE                     0-26483              94-3236309
(State or other jurisdiction of         (Commission         (I.R.S. Employer    
 incorporation or organization)         File Number)      Identification Number)

 1000 MARINA BLVD., SUITE 200 BRISBANE, CALIFORNIA 94005
 (Address of Principal Administrative Offices)

 Registrants Telephone Number, Including Area Code: (650) 624-1000

8-K
2nd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 2nd
Item 5. Other Events.                                                           

On October 3, 2002, VaxGen, Inc. (the "Company") announced that the Company has 
been awarded a $13.6 million contract from the National Institute of Allergy and
Infectious Diseases (NIAID), part of the U.S. National Institutes of Health     
(NIH), to develop a new anthrax vaccine and to create a feasibility plan to     
manufacture an emergency stockpile of 25 million doses.                         

The press release is filed herewith as Exhibit 99.1 and incorporated herein by  
reference.                                                                      

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.     

(c)   Exhibits.                                                                 

EXHIBIT      DESCRIPTION                                            

99.1         Press Release issued October 3, 2002.                  

8-K
3rd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 3rd
 SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the        
registrant has duly caused this report to be signed on its behalf by the        
undersigned hereunto duly authorized.                                           

                                        VaxGen, Inc.
                                          (Registrant)

Dated: October 4, 2002                                By:  /s/ Carter A. Lee    
                                                      --------------------------
                                         Carter A. Lee
                                                 Senior Vice President
                                                    Finance & Administration

8-K
Last Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 4th
 EXHIBIT INDEX

EXHIBIT No.      DESCRIPTION                                              
-----------      -----------                                              

99.1          Press Release issued October 3, 2002.                 

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on:		10/4/02		3
For Period End:		10/3/02		1		4			424B3
									List all Filings